Health benefit: Women’s health

A new approach to women’s health

Long underrepresented in medical research, women’s health is today experiencing a true transformation, with increasingly targeted solutions being developed for each stage of life (premenstrual syndrome, endometriosis, perinatal health, menopause, etc.).

Premenstrual syndrome (PMS) affects the majority of women of reproductive age and is associated with physical and emotional symptoms that significantly impact quality of life.

Its causes are multifactorial⁴, including:

Hormonal fluctuations throughout the menstrual cycle
Genetic predisposition
Psychological and environmental factors
Oxidative stress and chronic inflammation⁴

Premenstrual syndrome affects between 30% and 50% of women of reproductive age¹˒²

1 in 2 women experiences menstrual pain³

PMS: Why target oxidative stress and inflammation? ?

Premenstrual syndrome (PMS) is not limited to temporary symptoms. It reflects deeper biological imbalances, particularly oxidative stress and chronic inflammation⁴.

Recent research shows that these two mechanisms play a central role in the intensity of both physical symptoms (pain, migraines, discomfort) and emotional symptoms (anxiety, irritability, depression)⁴˒⁵.

Inflammation: Elevated inflammatory markers (IL‑2, IL‑4, IL‑10, IL‑12, IL‑6, TNF‑α, CRP) are associated with PMS symptoms such as migraines, pain, and physical discomfort⁴.
Oxidative stress: Increased levels of reactive oxygen species (ROS) can alter neuronal function, leading to mood fluctuations, anxiety, depression, as well as increased appetite and weight gain⁴.

Addressing these root causes of PMS goes beyond temporary symptom relief, offering a comprehensive, sustainable, and targeted approach to reducing both the emotional and physical symptoms associated with PMS.

SULFODYNE®: a complete solution for PMS management

Sulforaphane, the active compound in SULFODYNE®, helps reduce oxidative stress, control inflammation, and provides a neuroprotective effect, thereby offering a scientifically supported, comprehensive approach to managing both the physical and emotional symptoms of PMS.

Antioxidant effect

Reduction of reactive oxygen species (ROS): decreased oxidative stress⁶˒⁷
Activation of the Nrf2 pathway, a key mechanism in cellular protection⁸
Neuroprotection through modulation of BDNF, GABA, and glutamate levels, resulting in antidepressant and anxiolytic effects⁹˒¹⁰

Anti-inflammatory effect

Inhibition of the NF‑κB pathway, leading to reduced production of pro‑inflammatory mediators such as IL‑6, IL‑1β, and TNF‑α⁶˒¹¹
Inhibition of enzymes involved in pain and inflammation, including NOS, COX‑1, and COX‑2¹¹˒¹²
Relief of pain¹¹˒¹²

Proven effectiveness of SULFODYNE® in real‑world study

A real‑world observational study was conducted in 50 women suffering from premenstrual syndrome (PMS), using a dosage of 2 × 200 mg of SULFODYNE® per day, administered seven days before menstruation and during the first three days of menstruation, over three consecutive cycles¹³.

Key Results

84% reported a reduction in PMS‑related discomfort
More than 90% reported an improvement in emotional well‑being
More than 90% experienced a reduction in pain
94% reported a rapid effect from the very first cycle
86% observed an improvement in overall quality of life with SULFODYNE®
94% considered that SULFODYNE® acts quickly, starting from the first cycle
86% stated they would be willing to purchase SULFODYNE®

SULFODYNE®: a trusted ally for women’s health

Through its action on inflammation and oxidative stress, SULFODYNE® may also help support other important stages of women’s health:

Endometriosis is a condition in which inflammation plays a major role. Preliminary in vivo studies suggest that sulforaphane may:

- Reduce the volume of endometriotic lesions¹⁴
- Decrease the adhesion of endometriotic lesions¹⁴
- Exert antinociceptive and anti‑inflammatory effects in an in vivo endometriosis model¹⁵

Menopause: extensive scientific data indicate that excess oxidative stress and chronic inflammation are associated with several menopause‑related disorders, including: depression¹⁶. osteoporosis¹⁷. neurodegenerative diseases¹⁸. increased risk of cardiovascular diseases¹⁹. By modulating oxidative stress and inflammatory pathways, sulforaphane may contribute to supporting overall health and well‑being during menopause.

References

1 : Rezende et al., 2022 ; 2 : Modzelewski et al., 2024 ; 3 : Étude IFOP, mai 2021 ; 4 : Sultana et al., 2022 ; 5 : Azlan et al., 2020 ; 6 : Ruhee & Suzuki, 2020 ; 7 : Chen M, et al., 2021 ; 8 : Romeo et al., 2024 ; 9 : Martin-de-Saavedra et al., 2013 ; 10 : Ferreira-Chamorro et al., 2018 ; 11 : Liu et al., 2020 ; 12 : Guadarrama-Enriquez et al., 2023 ; 13 : SULFODYNE® real-life study carried out by an independent research institute on 50 women in France in 2024 ; 14 : Zhou and al., 2020 ; 15 : Liu et al., 2020 ; 16 : Zhang et al., 2024 ; 17 : Wu et al., 2021 ; 18 : McCarthy & Raval, 2020 ; 19 : Cabre et al., 2024